Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > anyone know

<< Previous

Bullboard Posts

Next >>

Comment by MustangSalleyon May 20, 2021 11:24pm

129 Views

Post# 33246160

RE:RE:RE:RE:RE:RE:RE:RE:anyone know

cowjazz wrote:
Why are you linking the bought deal with your mythical investor dumping 10 million shares above $2.00? The bought deal was announced Feb. 24 and closed March 1, well after the SP made it above $2.00 (for two days:closed at $2.42 on Jan.18 and $2:13 on Feb. 7). If this investor dumped 10 million shares above $2.00, it was to MAKE MONEY, not out of some righteous indignation regarding Dr. T. They hadn't even announced the bought deal at that point and Mr. MoneyBags would have loved management for creating a momentary rocket to the moon...just as I did.

You're cherry picking without any regard to the timeline.

My point here is that this investor does not believe in Toleikis that he can deliver and execute . So much so he won't buy back at all. This is a sophisticated investor that put up $1 million for despatate Toleikis at 25 cents to get the immunotherapy technology to which Toleikis has done nothing with . Smart money is hoping clinical results from DrW and anything coupled with any pharma deal will create enough liquidity to exit their large positions .

Only a month to see what transpires .

The share price was well over $2 when Leeds Jones put out a target price below the trading price while negiotationg a cheap bought deal. You think a bought deal at $1.20 had anything to do with share price gravitating to that level and staying there? Well it's 1.30 with constant selling . Just fluff news releases from your hero Dr T .

Ms Sally